BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23793291)

  • 21. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
    Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
    J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural basis of substrate discrimination and integrin binding by autotaxin.
    Hausmann J; Kamtekar S; Christodoulou E; Day JE; Wu T; Fulkerson Z; Albers HM; van Meeteren LA; Houben AJ; van Zeijl L; Jansen S; Andries M; Hall T; Pegg LE; Benson TE; Kasiem M; Harlos K; Kooi CW; Smyth SS; Ovaa H; Bollen M; Morris AJ; Moolenaar WH; Perrakis A
    Nat Struct Mol Biol; 2011 Feb; 18(2):198-204. PubMed ID: 21240271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autotaxin inhibitors: a patent review.
    Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
    Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.
    Balupuri A; Lee DY; Lee MH; Chae S; Jung E; Kim Y; Ryu J; Kang NS
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4156-4164. PubMed ID: 28743508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
    Barbayianni E; Kaffe E; Aidinis V; Kokotos G
    Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects.
    Lei H; Li C; Yang Y; Jia F; Guo M; Zhu M; Jiang N; Zhai X
    Eur J Med Chem; 2020 Sep; 201():112456. PubMed ID: 32535330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of metastasis of intravenously-inoculated B16/F10 melanoma cells by the novel ginseng-derived ingredient, gintonin: involvement of autotaxin inhibition.
    Hwang SH; Lee BH; Kim HJ; Cho HJ; Shin HC; Im KS; Choi SH; Shin TJ; Lee SM; Nam SW; Kim HC; Rhim H; Nah SY
    Int J Oncol; 2013 Jan; 42(1):317-26. PubMed ID: 23174888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
    Baker DL; Fujiwara Y; Pigg KR; Tsukahara R; Kobayashi S; Murofushi H; Uchiyama A; Murakami-Murofushi K; Koh E; Bandle RW; Byun HS; Bittman R; Fan D; Murph M; Mills GB; Tigyi G
    J Biol Chem; 2006 Aug; 281(32):22786-93. PubMed ID: 16782709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacophoric Site Identification and Inhibitor Design for Autotaxin.
    Lee MH; Lee DY; Balupuri A; Jeong JW; Kang NS
    Molecules; 2019 Aug; 24(15):. PubMed ID: 31374894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
    Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
    FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors.
    Cui P; McCalmont WF; Tomsig JL; Lynch KR; Macdonald TL
    Bioorg Med Chem; 2008 Mar; 16(5):2212-25. PubMed ID: 18082408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis for specific inhibition of Autotaxin by a DNA aptamer.
    Kato K; Ikeda H; Miyakawa S; Futakawa S; Nonaka Y; Fujiwara M; Okudaira S; Kano K; Aoki J; Morita J; Ishitani R; Nishimasu H; Nakamura Y; Nureki O
    Nat Struct Mol Biol; 2016 May; 23(5):395-401. PubMed ID: 27043297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors.
    Banerjee S; Norman DD; Deng S; Fakayode SO; Lee SC; Parrill AL; Li W; Miller DD; Tigyi GJ
    Bioorg Chem; 2020 Oct; 103():104188. PubMed ID: 32890995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of non-lipid autotaxin inhibitors.
    Hoeglund AB; Howard AL; Wanjala IW; Pham TC; Parrill AL; Baker DL
    Bioorg Med Chem; 2010 Jan; 18(2):769-76. PubMed ID: 20005724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
    Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
    ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
    Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
    J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
    Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
    Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
    Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
    Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
    Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
    Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
    Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
    J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.